Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RMTI
RMTI logo

RMTI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Rockwell Medical Inc (RMTI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.100
1 Day change
8.93%
52 Week Range
21.000
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

RMTI is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has short-term upside potential after the reverse split news, but the overall setup is still weak: bearish moving averages, negative MACD, no bullish proprietary signal, and no strong financial or analyst support provided. If you are impatient and want to act now, this is still more of a hold than a clean buy.

Technical Analysis

The current trend is weak to mildly improving. MACD histogram is -0.0677 and still below zero, so momentum remains bearish. RSI_6 at 32.28 is near oversold but not a strong reversal signal. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, showing the longer-term trend is still down. Price at 5.5595 is below the pivot at 6.017 and only slightly above support at 5.21, which means downside risk is still present. Near-term trend data also suggests only modest upside probabilities, not a strong breakout setup.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment looks extremely bullish on paper because put-call open interest is very low at 0.04, meaning call positioning dominates. However, actual option volume is zero, so there is no active trading confirmation. Implied volatility is extremely high (30d IV 976.62, IV percentile 100), which signals elevated expectations and uncertainty rather than a clean directional conviction. Net: sentiment is call-heavy, but the lack of volume makes it less reliable.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
3

Positive Catalysts

  • ["Reverse stock split effective July 1, 2026 may help regain Nasdaq compliance.", "The board says the split may help attract institutional investors.", "Price had a positive regular session move of 6.74%, showing some short-term buying interest."]

Neutral/Negative Catalysts

  • ["Reverse stock split is a compliance-driven action, which often reflects prior weakness.", "Bearish technical trend remains intact with MACD below zero and bearish moving averages.", "No AI Stock Picker signal and no recent SwingMax buy signal.", "Hedge funds and insiders are both neutral with no meaningful accumulation trends.", "No recent congress trading activity reported.", "No financial snapshot was available, so there is no evidence here of accelerating fundamentals."]

Financial Performance

No latest-quarter financial data was provided, so there is no basis to confirm revenue growth, earnings improvement, or margin expansion. Because the latest quarter season is unavailable, the financial picture cannot support a strong long-term buy case at this time.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided. Based on the available Wall Street-style view, the pros are the compliance fix from the reverse split and possible institutional interest, while the cons are weak price structure, no clear fundamental support, and no bullish signal from sentiment or positioning. Overall, Wall Street support cannot be considered strong from the available data.

Wall Street analysts forecast RMTI stock price to fall
2 Analyst Rating
Wall Street analysts forecast RMTI stock price to fall
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.600
sliders
Low
2.5
Averages
3.75
High
5
Current: 5.600
sliders
Low
2.5
Averages
3.75
High
5
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$2
AI Analysis
2026-03-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$2
AI Analysis
2026-03-30
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Rockwell Medical to $2 from $2.50 and keeps a Buy rating on the shares. The firm cites the company's "more modest" sales ramp for the target cut.
Maxim
Maxim
Buy
maintain
$5 -> $4
2026-03-27
Reason
Maxim
Maxim
Price Target
$5 -> $4
2026-03-27
maintain
Buy
Reason
Maxim lowered the firm's price target on Rockwell Medical (RMTI) to $4 from $5 and keeps a Buy rating on the shares. The firm cites the company's Q4 results with net sales below better-than-expected preliminary net sales, the analyst tells investors in a research note. Maxim further notes that while Rockwell continues to position itself within the at-home dialysis market, a growing segment that now accounts for roughly 10% of the total hemodialysis market, the firm is reducing its estimates given continued pressure from lower DaVita (DVA) contribution and limited visibility on certain revenue contributions.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RMTI
Unlock Now

People Also Watch